SCHEMBL17059208

SCHEMBL17059208

COc1cc(N2CCN(C)CC2)c(N)cc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.53
DRD3 P35462 3/20 0.53
KDM4E B2RXH2 4/20 0.51
MAPT P10636 2/20 0.51
GAA P10253 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
RECQL P46063 1/20 0.51
PTK2B Q14289 1/20 0.51
ALDH1A1 P00352 3/20 0.50
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ADRA2C P18825 1/20 0.47
HSD17B10 Q99714 1/20 0.45
RAD52 P43351 1/20 0.42
S100B P04271 1/20 0.41
DRD4 P21917 2/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29930028 1.00 DRD2 (0.53) DRD2DRD3KDM4EMAPTGAA
SCHEMBL1911914 0.90 DRD2 (0.53) DRD2DRD3KDM4EMAPTGAA
SCHEMBL17164753 0.87 DRD2 (0.50) DRD2DRD3KDM4EMAPTGAA
SCHEMBL29508932 0.87 DRD2 (0.50) DRD2DRD3KDM4EMAPTGAA
SCHEMBL24251759 0.86 ALDH1A1 (0.50) KDM4EMAPTGAAMAPK1HTT
SCHEMBL22520158 0.85 FGFR3 (0.42) DRD2DRD3KDM4EMAPTGAA
SCHEMBL22858439 0.85 MAPT (0.54) DRD2DRD3KDM4EMAPTGAA
SCHEMBL12491827 0.85 POLB (0.53) DRD2DRD3KDM4EMAPTGAA
SCHEMBL12714785 0.85 ALDH1A1 (0.50) DRD2DRD3KDM4EMAPTGAA
SCHEMBL29508898 0.85 MAPT (0.54) DRD2DRD3KDM4EMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2844642-B1 COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS ARIAD PHARMA INC (US) 2019-11-13 EP disclosed
US-20180009782-A1 PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE BETTA PHARMACEUTICALS CO., LTD. (CN) 2018-01-11 US disclosed
EP-3112364-A1 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) 2017-01-04 EP disclosed
WO-2015127872-A1 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM 上海海雁医药科技有限公司 2015-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009782-A1 PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE ALK, EGFR, ERBB2 DRD2 4768/4885DRD3 4832/4885KDM4E 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.